- Home
- ATNM vs ESLA Comparison
ATNM vs ESLA Comparison
Compare ATNM & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- ESLA
- Stock Information
- Founded
- ATNM 2000
- ESLA 2021
- Country
- ATNM United States
- ESLA United States
- Employees
- ATNM N/A
- ESLA N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATNM Health Care
- ESLA Health Care
- Exchange
- ATNM Nasdaq
- ESLA Nasdaq
- Market Cap
- ATNM 50.2M
- ESLA 48.9M
- IPO Year
- ATNM N/A
- ESLA N/A
- Fundamental
- Price
- ATNM $1.29
- ESLA $2.68
- Analyst Decision
- ATNM Strong Buy
- ESLA Strong Buy
- Analyst Count
- ATNM 2
- ESLA 1
- Target Price
- ATNM $4.50
- ESLA $16.00
- AVG Volume (30 Days)
- ATNM 306.1K
- ESLA 510.7K
- Earning Date
- ATNM 11-14-2025
- ESLA 11-13-2025
- Dividend Yield
- ATNM N/A
- ESLA N/A
- EPS Growth
- ATNM N/A
- ESLA N/A
- EPS
- ATNM N/A
- ESLA N/A
- Revenue
- ATNM N/A
- ESLA N/A
- Revenue This Year
- ATNM N/A
- ESLA N/A
- Revenue Next Year
- ATNM N/A
- ESLA N/A
- P/E Ratio
- ATNM N/A
- ESLA N/A
- Revenue Growth
- ATNM N/A
- ESLA N/A
- 52 Week Low
- ATNM $1.03
- ESLA $0.70
- 52 Week High
- ATNM $2.41
- ESLA $3.15
- Technical
- Relative Strength Index (RSI)
- ATNM 40.17
- ESLA 59.04
- Support Level
- ATNM $1.23
- ESLA $2.20
- Resistance Level
- ATNM $1.40
- ESLA $3.01
- Average True Range (ATR)
- ATNM 0.09
- ESLA 0.44
- MACD
- ATNM -0.01
- ESLA 0.01
- Stochastic Oscillator
- ATNM 19.61
- ESLA 61.54
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.